HomeCompareOSOPF vs PFE

OSOPF vs PFE: Dividend Comparison 2026

OSOPF yields 2682.25% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 OSOPF wins by $2273.97M in total portfolio value
10 years
OSOPF
OSOPF
● Live price
2682.25%
Share price
$0.00
Annual div
$0.02
5Y div CAGR
-36.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2274.02M
Annual income
$292,561,511.61
Full OSOPF calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — OSOPF vs PFE

📍 OSOPF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodOSOPFPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, OSOPF + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
OSOPF pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

OSOPF
Annual income on $10K today (after 15% tax)
$227,991.25/yr
After 10yr DRIP, annual income (after tax)
$248,677,284.87/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, OSOPF beats the other by $248,654,155.91/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of OSOPF + PFE for your $10,000?

OSOPF: 50%PFE: 50%
100% PFE50/50100% OSOPF
Portfolio after 10yr
$1137.03M
Annual income
$146,294,361.07/yr
Blended yield
12.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

OSOPF
No analyst data
Altman Z
2.0
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

OSOPF buys
0
PFE buys
0
No recent congressional trades found for OSOPF or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricOSOPFPFE
Forward yield2682.25%6.20%
Annual dividend / share$0.02$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-36.4%13.2%
Portfolio after 10y$2274.02M$51.1K
Annual income after 10y$292,561,511.61$27,210.54
Total dividends collected$1927.39M$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: OSOPF vs PFE ($10,000, DRIP)

YearOSOPF PortfolioOSOPF Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$181,291$170,591.10$9,161$701.38+$172.1KOSOPF
2$2,032,238$1,838,256.84$8,610$859.79+$2.02MOSOPF
3$14,422,848$12,248,352.65$8,366$1,081.25+$14.41MOSOPF
4$67,101,131$51,668,683.95$8,483$1,405.66+$67.09MOSOPF
5$214,680,882$142,882,671.40$9,084$1,907.24+$214.67MOSOPF
6$501,425,304$271,716,761.24$10,418$2,732.78+$501.41MOSOPF
7$913,751,967$377,226,890.97$13,007$4,193.56+$913.74MOSOPF
8$1,386,314,320$408,599,715.67$18,010$7,005.87+$1386.30MOSOPF
9$1,851,828,569$368,472,246.93$28,216$12,979.89+$1851.80MOSOPF
10$2,274,018,081$292,561,511.61$51,081$27,210.54+$2273.97MOSOPF

OSOPF vs PFE: Complete Analysis 2026

OSOPFStock

Osotspa Public Company Limited, together with its subsidiaries manufactures and distributes energy drinks and personal care products worldwide. The company operates in three segments: Beverage, Personal Care, and Others. It offers energy drinks under the M-150, Lipovitan-D, Chalarm, Som in-Sum, White Shark, Shark Energy Drink, and M-Storm brand names; ready-to drink coffee under the M-Presso name; sport drinks under the M-Electrolyte brand; and functional drinks under the Peptein, Peptein Gold, C-Vitt, Calpis Lacto, and Slimma brands. The company also provides baby care products under the Babi Mild brand name; male grooming products under the Exit brand; women beauty care products under the Twelve Plus, Plantstory, Ole Strwaberry, PROhada, and OTG brands; healthcare products under the KRISNAKLAN, Utaitip, Tamjai, YATHAD 4, Yixin, and BANNER brands; and confectionery products under the Botan and Ole brand names. In addition, it provides marketing and property rental services; manufactures and distributes glass, and beverage concentrates and premixes; and distributes food, beverages, and cullet products. Further, the company engages in the import, retail, and wholesale of beverages; investing in other companies; provision of research and development services; electronic commerce business; and education and sale of herbal products. Additionally, it obtains licensing fee for use of trademark, as well as offers manufacturing and distribution services. Osotspa Public Company Limited was founded in 1891 and is based in Bangkok, Thailand.

Full OSOPF Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this OSOPF vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

OSOPF vs SCHDOSOPF vs JEPIOSOPF vs OOSOPF vs KOOSOPF vs MAINOSOPF vs JNJOSOPF vs MRKOSOPF vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.